Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval
References (22)
- et al.
Quinolone-resistant Neisseria gonorrhoeae
J Infect Chemother
(1997) - et al.
Determination of a new orally active cephalosporin in human plasma and urine by high-performance liquid chromatography using automated column switching
J Chromatogr
(1984) - et al.
A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan
J Infect Chemother
(2002) Guidelines for treatment of sexually transmitted diseases, 2002
Morbid Mortal Weekly Rep
(2002)- et al.
Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis
Drugs
(1999) - et al.
Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary
Sex Transm Dis
(1994) - et al.
Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998
J Clin Pathol
(2000) - et al.
Pharmacokinetic determinants of penicillin cure of gonococcal urethritis
Antimicrob Agents Chemother
(1979) - et al.
Drugs of choice for the treatment of uncomplicated gonococcal infections
Clin Infect Dis
(1995) Sexually transmitted disease surveillance 1999, supplement., Gonococcal Isolate Surveillance Project (GISP) annual report – 1999
(2000)
A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group
N Engl J Med
Cited by (95)
The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016–2017
2023, Journal of Infection and ChemotherapyThe JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders
2021, Journal of Infection and ChemotherapyCitation Excerpt :Third generation oral cephalosporins cannot be selected for treatment, because their resistance rates are 30–50%. CFIX, which has the strongest anti-gonococcal activity among the oral cephalosporins, is effective to an extent by a regimen of 200 mg at a time, twice a day, for 1–3 days, but many cases of poor response have been reported [63–65] (II, B). Sales of CDZM, which used to be recommended, were discontinued at the end of March 2016.
Antimicrobial resistance and molecular characterisation of Neisseria gonorrhoeae isolates in Fukuoka, Japan, 1996–2016
2019, Journal of Global Antimicrobial ResistanceCitation Excerpt :However, the CLSI does not define resistance to azithromycin, cefixime or ceftriaxone, therefore clinical breakpoints set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used for interpretation of susceptibility results for these three antimicrobial agents [17]. Furthermore, gonococcal isolates with an ESC MIC of only 0.125 mg/L have resulted in treatment failures with ESCs [18], thus in the present study in vitro decreased susceptibility to cefixime and ceftriaxone was defined as an MIC of 0.125 mg/L. β-Lactamase production was detected using a nitrocefin-based assay (Cefinase™ disk; Becton Dickinson, Sparks, MD) according to the manufacturer’s instructions. All 400 gonococcal isolates were analysed using NG-MAST molecular typing as described previously [19].
Identification and expression analysis of ceftriaxone resistance-related genes in Neisseria gonorrhoeae integrating RNA-Seq data and qRT-PCR validation
2019, Journal of Global Antimicrobial ResistanceClinical pharmacokinetics of cefixime: a systematic review
2023, Xenobiotica